Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 2, 2011, Pages

  Crajoinas, Renato O ^a   Oricchio, Felipe T ^a   Pessoa, Thaissa D ^a   Pacheco, Bruna P M ^a   Lessa, Lucília M A ^a   Malnic, Gerhard ^a   Girardi, Adriana C C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Protein kinase A; Proximal tubule; Renal hemodynamics

Indexed keywords

BICARBONATE; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; MESSENGER RNA; POTASSIUM; SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CELL FUNCTION; CONTROLLED STUDY; DIURESIS; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; MALE; MEMBRANE VESICLE; MICROVILLUS; MICTURITION; MOLECULAR MECHANICS; NATRIURESIS; NEPHRON; NONHUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SODIUM EXCRETION; URINARY EXCRETION;

EID: 79961180020     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00729.2010     Document Type: Article

References (40)

1. Agarwal R. Rapid microplate method for PAH estimation. Am J Physiol Renal Physiol 283: F236-F241, 2002.
2. + gradient the sugar transport. J Membr Biol 42: 81-98, 1978.
3. Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 3: 245-259, 2009.
4. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350, 2008.
5. Biemesderfer D, Rutherford PA, Nagy T, Pizzonia JH, Abu-Alfa AK, Aronson PS. Monoclonal antibodies for high-resolution localization of NHE3 in adult and neonatal rat kidney. Am J Physiol Renal Physiol 273: F289-F299, 1997.
6. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
7. Campbell RK, White JR. More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ 34: 518-534, 2008.
8. + exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 297: F1647-F1655, 2009.
9. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 288: R1695-R1706, 2005.
10. Crajoinas RO, Lessa LM, Carraro-Lacroix LR, Davel AP, Pacheco BP, Rossoni LV, Malnic G, Girardi AC. Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHR. Am J Physiol Renal Physiol 299: F872-F881, 2010.
11. Donowitz M, Li X. Regulatory binding partners and complexes of NHE3. Physiol Rev 87: 825-872, 2007.
12. Drucker DJ. Biologic actions and therapeutic potential of the progluca-gon-derived peptides. Nat Clin Pract Endocrinol Metab 1: 22-31, 2005.
13. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 19: 403-418, 1992.
14. Gallwitz B, Witt M, Folsch UR, Creutzfeldt W, Schmidt WE. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J Mol Endocrinol 10: 259-268, 1993.
15. + exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 276: 46671-46677, 2001.
16. + exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 294: F414-F422, 2008.
17. + exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol 287: C1238-C1245, 2004.
18. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478: 136-142, 2008.
19. Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Stanga Z, Vogel D, Beglinger C. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73: 142-150, 2006.
20. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyen-buehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89: 3055-3061, 2004.
21. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 380: 44-49, 2009.
22. Holst JJ. Enteroglucagon. Annu Rev Physiol 59: 257-271, 1997.
23. Kocinsky HS, Dynia DW, Wang T, Aronson PS. NHE3 phosphorylation at serines 552 and 605 does not directly affect NHE3 activity. Am J Physiol Renal Physiol 293: F212-F218, 2007.
24. + exchanger NHE3 at PKA consensus sites. Am J Physiol Renal Physiol 289: F249-F258, 2005.
25. Kriz W, Bankir L. A standard nomenclature for structures of the kidney. The Renal Commission of the International Union of Physiological Sciences (IUPS). Kidney Int 33: 1-7, 1988.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
27. Laugero KD, Stonehouse AH, Guss S, Landry J, Vu C, Parkes DG. Exenatide improves hypertension in a rat model of the metabolic syndrome. Metab Syndr Relat Disord 7: 327-334, 2009.
28. Malnic G, Klose RM, Giebisch G. Micropuncture study of renal potassium excretion in the rat. Am J Physiol 206: 674-686, 1964.
29. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434: 163-167, 2002.
30. Moriyama T, Murphy HR, Martin BM, Garcia-Perez A. Detection of specific mRNAs in single nephron segments by use of the polymerase chain reaction. Am J Physiol Renal Fluid Electrolyte Physiol 258: F1470-F1474, 1990.
31. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125: 173-177, 2005.
32. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215, 2004.
33. Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, Girardi AC. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 29: 520-528, 2011.
34. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest 46: 1954-1962, 1967.
35. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51: 943-950, 2002.
36. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141: 120-128, 2007.
37. + exchanger subtype 3 in various cell types. Pflügers Arch 436: 797-800, 1998.
38. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 26: 869-879, 1995.
39. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613, 2001.
40. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21: 1125-1135, 2003.